CSL
COMSTOCK METALS LTD
stock CVE

What’s interesting about CRDL right now isn’t just the company itself, it’s what’s happening around it. 
Over the last few months you’ve had Lilly go out and buy Ventyx for about $1.2B, Novartis signing that Monte Rosa deal that can run up to $5.7B, and then the CSL / Lilly licensing deal with real upfront money attached. Different situations, but they all point in the same direction. Big pharma is spending again on inflammation-related assets. 
CRDL just happens to be sitting there with a Phase 3 already running and actual clinical data behind it. That’s not the same as those earlier-stage platform stories, but it’s also not disconnected from that trend either. 
Feels like one of those situations where the company didn’t change overnight, but the environment around it did. 

What’s interesting about CRDL right now isn’t just the company itself, it’s what’s happening around it. 
Over the last few months you’ve had Lilly go out and buy Ventyx for about $1.2B, Novartis signing that Monte Rosa deal that can run up to $5.7B, and then the CSL / Lilly licensing deal with real upfront money attached. Different situations, but they all point in the same direction. Big pharma is spending again on inflammation-related assets. 
CRDL just happens to be sitting there with a Phase 3 already running and actual clinical data behind it. That’s not the same as those earlier-stage platform stories, but it’s also not disconnected from that trend either. 
Feels like one of those situations where the company didn’t change overnight, but the environment around it did.